Protocadherin-17 promoter methylation in serum-derived DNA is associated with poor prognosis of bladder cancer

Journal of International Medical Research

Volumn 42, Issue 1, 2014, Pages 35-41

  Luo, Zhen Guo ^a   Li, Zhi Gang ^b   Gui, Shi Liang ^a   Chi, Bao Jin ^a   Ma, Jian Guo ^c  

^a JIAMUSI UNIVERSITY   (China)

^b The General Hospital of CNPC   (China)

^c HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; bladder cancer; methylation; prognosis; protocadherin 17

Indexed keywords

BIOLOGICAL MARKER; CADHERIN; PROTOCADHERIN 17; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CONTROLLED STUDY; DNA ISOLATION; DNA METHYLATION; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; ONCOGENE; OVERALL SURVIVAL; PCDH17 GENE; POLYMERASE CHAIN REACTION; PROMOTER REGION; VERY ELDERLY;

BIOMARKER; BLADDER CANCER; METHYLATION; PROGNOSIS; PROTOCADHERIN-17;

ADULT; AGED; AGED, 80 AND OVER; CADHERINS; CASE-CONTROL STUDIES; DNA; DNA METHYLATION; DNA PRIMERS; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84892447557     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060513504705     Document Type: Article

References (28)

1. Siegel R,Naishadham D,Jemal A.Cancer statistics, 2013.CA Cancer J Clin. 2013;63:11-30.
2. Ploeg M,Aben KK,Kiemeney LA.The present and future burden of urinary bladder cancer in the world.World J Urol. 2009;27:289-293.
3. Jichlinski P.New diagnostic strategies in the detection and staging of bladder cancer.Curr Opin Urol. 2003;13:351-355.
4. Lin YL,Sun G,Liu XQ, et al.Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma.J Int Med Res. 2011;39:179-186.
5. Frantzi M,Makridakis M,Vlahou A.Biomarkers for bladder cancer aggressiveness.Curr Opin Urol. 2012;22:390-396.
6. Han H,Wolff EM,Liang G.Epigenetic alterations in bladder cancer and their potential clinical implications.Adv Urol. 2012;2012:546917-546917.
7. Yegin Z,Gunes S,Buyukalpelli R.Hypermethylation of TWIST1 and NID2 in tumor tissues and voided urine in urinary bladder cancer patients.DNA Cell Biol. 2013;32:386-392.
8. Heyn H,Esteller M.DNA methylation profiling in the clinic: applications and challenges.Nat Rev Genet. 2012;13:679-692.
9. Li L,Choi JY,Lee KM, et al.DNA methylation in peripheral blood: a potential biomarker for cancer molecular epidemiology.J Epidemiol. 2012;22:384-394.
10. Balgkouranidou I,Karayiannakis A,Matthaios D, et al.Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival.Clin Chem Lab Med. 2013;51:1505-1510.
11. Van De Voorde L,Speeckaert R,Van Gestel D, et al.DNA methylation-based biomarkers in serum of patients with breast cancer.Mutat Res. 2012;751:304-325.
12. Hu X,Sui X,Li L, et al.Protocadherin 17 acts as a tumour suppressor inducing tumour cell apoptosis and autophagy, and is frequently methylated in gastric and colorectal cancers.J Pathol. 2013;229:62-73.
13. Yang Y,Liu J,Li X, et al.PCDH17 gene promoter demethylation and cell cycle arrest by genistein in gastric cancer.Histol Histopathol. 2012;27:217-224.
14. Costa VL,Henrique R,Danielsen SA, et al.TCF21 and PCDH17 methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers.Epigenetics. 2011;6:1120-1130.
15. Oosterlinck W,Lobel B,Jakse G, et al.Guidelines on bladder cancer.Eur Urol. 2002;41:105-112.
16. Lin YL,Li ZG,He ZK, et al.Clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in bladder cancer.J Int Med Res. 2012;40:2117-2123.
17. Kandimalla R,van Tilborg AA,Kompier LC, et al.Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.Eur Urol. 2012;61:1245-1256.
18. Kim EJ,Kim YJ,Jeong P, et al.Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor.J Urol. 2008;180:1141-1145.
19. Hoque MO,Begum S,Brait M, et al.Tissue inhibitor of metalloproteinases-3 promoter methylation is an independent prognostic factor for bladder cancer.J Urol. 2008;179:743-747.
20. Kulis M,Esteller M.DNA methylation and cancer.Adv Genet. 2010;70:27-56.
21. Suvà ML,Riggi N,Bernstein BE.Epigenetic reprogramming in cancer.Science. 2013;339:1567-1570.
22. Heyn H,Méndez-González J,Esteller M.Epigenetic profiling joins personalized cancer medicine.Expert Rev Mol Diagn. 2013;13:473-479.
23. Delpu Y,Cordelier P,Cho WC, et al.DNA methylation and cancer diagnosis.Int J Mol Sci. 2013;14:15029-15058.
24. Roossink F,de Jong S,Wisman GB, et al.DNA hypermethylation biomarkers to predict response to cisplatin treatment, radiotherapy or chemoradiation: the present state of art.Cell Oncol (Dordr). 2012;35:231-241.
25. Marsit C,Christensen B.Blood-derived DNA methylation markers of cancer risk.Adv Exp Med Biol. 2013;754:233-252.
26. Sturgeon SR,Balasubramanian R,Schairer C, et al.Detection of promoter methylation of tumor suppressor genes in serum DNA of breast cancer cases and benign breast disease controls.Epigenetics. 2012;7:1258-1267.
27. Jacobs BL,Lee CT,Montie JE.Bladder cancer in 2010: how far have we come?.CA Cancer J Clin. 2010;60:244-272.
28. Sharma S,Ksheersagar P,Sharma P.Diagnosis and treatment of bladder cancer.Am Fam Physician. 2009;80:717-723.